Myasthenia gravis as a form of clinical presentation of thymic carcinoma

Abstract

Thymic carcinomas are rare tumors of the thymus arising in the thymic epithelium. They represent less than 1% of thymic malignancies. They often present with an advanced disease and metastasize to regional lymph nodes and distant sites. They have a worse prognosis with a 5-year survival rate of 30%-50%, while thymomas are much less invasive and have a 5-year survival of approximately 78%. We report a rare form of clinical presentation of a thymic carcinoma in which the diagnosis of myasthenia gravis was the cornerstone of the diagnosis of cancer. Surgery is considered the salvage treatment when possible. Radiotherapy is a second choice of salvage treatment, when possible depending on its localization and relation to nearby structures such as vascular structures. Molecular target therapy is a more directed, more expensive but less toxic treatment. Further studies need to be carried out for its approval worldwide, outside clinical trials.

Key Words: Myasthenia gravis, Thymic carcinoma, Multidisciplinary approach, Clinical-molecular signature, Prognosis

Core tip: We report a rare form of clinical presentation of a thymic carcinoma in which the diagnosis of myasthenia gravis was the cornerstone of the diagnosis of cancer. Surgery is considered the salvage treatment when possible. Radiotherapy is a second choice of salvage treatment, when possible depending on its localization and relation to nearby structures such as vascular structures. The prognosis is very reserved, when neither surgery nor radiotherapy can be accomplished. Having an unfavorable molecular signature, less than 10% of thymic carcinomas have c-kit mutations, and clinical outcome of these patients is detrimental.

INTRODUCTION

Thymic epithelial neoplasms are rare, but are nowadays well-classified according to the Masaoka-Koga system which is the currently most widely used classification[1]. Thymic epithelial neoplasmas comprise thymomas, thymic carcinomas and thymic neuroendocrine tumors. Thymoma is the most common epithelial tumor in the anterior mediastinum in adults. Thymic carcinomas represent less than 1% of all thymic malignancies[2]. They have a worse prognosis with a 5-year survival rate of 30%-50%, while thymomas are much less invasive and have a 5-year survival of approximately 78%[2]. Treatment of thymic carcinomas may vary from complete surgical resection, being the gold standard, to chemotherapy and/or radiotherapy. The main aim of this case report is to share experience in dealing with the optimal treatment of a rare, indolent and malignant thymic carcinoma, where molecular pathways of thymic carcinomas are still on the verge of a new form of knowledge management.

CASE REPORT

A 76-year-old white man with previously known ischemic heart disease, hypertension, dyslipidemia and obstructive sleep apnea syndrome (with domiciliary continuous positive airway pressure), complained of cervical pain, sore throat, dysphagia and mild dyspnea over the past 2 wk. Due to sudden clinical deterioration he was evaluated in the emergency department. The cervical-thoracic-abdominal scan showed an anterior mediastinal mass measuring 66 mm × 60 mm in diameter, a slight pericardial effusion and a 14-mm pulmonary nodule in the right superior lobe (Figures 1 and 2).

Figure 1 Computed tomography thoracic scan showing an anterior mediastinal mass with lobular contours measuring 60 mm × 66 mm.

Figure 2 Computed tomography thoracic scan showing a 14-mm pulmonary nodule.

He was admitted to the Internal Medicine Department and started oxazepam. On the same day, he had a sudden worsening of conscious level and global respiratory insufficiency and was submitted to mechanical ventilation. The patient was transferred to the intensive care unit. The suspicion of myasthenic syndrome was confirmed by positivity to anticholinesterase antibodies. Two weeks later the patient improved and was extubated to spontaneous ventilation. An anterior mediastinal biopsy was performed and revealed a thymic carcinoma with squamous differentiation, which was poorly differentiated, positive for CD5 and negative for CD 117 and chromogranin. Thus, a type C (World Health Organization) stage IVB (Masaoka-Koga staging) (Figures 3 and 4) thymic carcinoma was diagnosed[1]. The laboratory testing revealed no abnormal values. The patient was transferred to the Internal Medicine Department, clinically improved and was discharged one week later.

Figure 3 High-power view of poorly differentiated non-keratinizing squamous thymic carcinoma.

Figure 4 Malignant epithelial tumor of the thymus positive for CD5 which favors thymic carcinoma over thymoma and tumors of non-thymic origin. A type C (World Health Organization) stage IVB (Masaoka- Koga Staging) thymic carcinoma was diagnosed.

The patient was evaluated by a multidisciplinary team and was diagnosed with a stage IVB disease (isolated pulmonary metastasis). Surgical hypothesis was rejected upfront given the vascular invasion of the tumor and highly suspected pulmonary metastasis. He started chemotherapy with carboplatin (area under the curve 6; D1) and paclitaxel (225 mg/m² D1) every 3 wk. The patient completed the 4^th cycle of chemotherapy with good tolerance and with a significant response on the computed tomography (CT) scan (Figures 5 and 6). No other secondary lesions were observed.

Figure 5 Computed tomography thoracic scan showing a 27 mm × 28 mm anterior mediastinal mass.

Figure 6 Computed tomography thoracic scan showing in the right superior lobe an 11-mm pulmonary nodule.

At this time he was evaluated by cardiothoracic surgery and due to his excellent response to chemotherapy, he was proposed for two more cycles and subsequent CT scan and PET-CT evaluation. Concerning a 76-year-old fit patient, surgery shall be considered at a later stage followed by postoperative radiotherapy if indicated.

DISCUSSION

Thymic carcinomas are aggressive tumors which often metastasize to distant sites. In the case, the high suspicion of myasthenia syndrome was confirmed and associated to thymic carcinoma (30%-50% cases)[3]. Total thymectomy and complete surgical excision are the gold standard of treatments and cisplatin-based chemotherapy is recommended in locally advanced, unresectable and metastatic setting.

Due to recent advances in technologies a better understanding of the molecular behavior of these tumors has been accomplished. Thymic carcinomas have a high frequency of KIT expression (73%-86%), but the rate of kit mutations remains low at 7%-9%[4]. Target therapies (imatinib or sunitinib) may be useful for patients with c-kit mutations besides its low expression[4]. Further molecular profiling for selecting the specific target therapy, is of upmost importance for defining the molecular signature of these tumors. Tumor characterization by clinical, imagiological and histological means are essential, but molecular profiling will allow us to treat our patients more efficiently, with better quality of life and lower toxicity profile.

Tumor stage, complete surgical resection and histology are the main prognostic factors of thymic carcinomas. Nevertheless, a very reserved prognosis when neither surgery nor radiotherapy can be accomplished is considered, but only 60% of the patients die from tumor progression. Other causes of death are autoimmune diseases and other non-malignant related disorders. Having an unfavorable molecular signature, less than 10% of thymic carcinomas have c-kit mutations, and clinical outcome of these patients is detrimental. Despite lacking data on second-line chemotherapy, it remains an option for these patients who present themselves with a recurring disease, with no indication for alternative therapies, namely molecular, surgical or even radiotherapy.

COMMENTS

Case characteristics

A 76-year-old man complained of cervical pain, sore throat, dysphagia and mild dyspnea over the past 2 wk.

Clinical diagnosis

Rapid clinical deterioration.

Differential diagnosis

Other etiologies of anterior mediastinal masses.

Laboratory diagnosis

An anterior mediastina biopsy was performed.

Imaging diagnosis

The cervical-thoracic-abdominal scan showed an anterior mediastinal mass measuring 66 mm × 60 mm in diameter.

Pathological diagnosis

A thymic carcinoma with squamous differentiation, which was poorly differentiated, positive for CD5 and negative for CD 117 and chromogranin. A type C (World Health Organization) stage IVB (Masaoka-Koga staging) thymic carcinoma was diagnosed.

Treatment

Chemotherapy with carboplatin (area under the curve 6; D1) and paclitaxel (225 mg/m² D1) every 3 wk.

Related reports

Thymic carcinomas have a high frequency of KIT expression (73%-86%), but the rate of kit mutations remains low at 7%-9%. Target therapies (imatinib or sunitinib) may be useful for patients with c-kit mutations.

Term explanation

Further molecular profiling for selecting the specific target therapy, is of upmost importance for defining the molecular signature of these tumors.

Experiences and lessons

Tumor characterization by clinical, imagiological and histological means is still vital, but molecular profiling will allow us to treat our patients more efficiently, with better quality of life and lower toxicity profile.

Peer-review

The paper is a report of a clinical case about thymic carcinoma that presented with signs and symptoms of a myasthenia gravis.